entertainment -WSS

entertainment

author：explore 2025-08-28 08:44:00 - browse：6366

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Intarcia’s device

entertainment

focus

entertainment

WSS

CommonSpirit Health keeps growing, even as it loses money

Senate HELP committee spars over health care workforce policies

Ukraine and a new approach to mental health in war

How the Dana

Data show record exodus of life scientists from academia

FDA seeks to regulate lab

knowledge

entertainment

entertainment

In Memoriam: Notable people who died in 2023

CDC advisers recommend seasonal use of Pfizer RSV shot

Activists slam private health insurers over coverage restrictions

STAT Virtual Event: Putting AI to the Test

The high cost of giving birth even with insurance

Intarcia’s device

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicaid, Medicare dual

Hollywood unions extend contract negotiations for actors

Thermo Fisher plant for manufacturing gene therapies to expand

leisure time

Researchers use wearables data and AI to predict preterm birth risk

Microbiome research is starting to find links to chronic diseases

FDA advisers vote against ALS treatment from BrainStorm

Researchers use wearables data and AI to predict preterm birth risk

It's been 20 years since Dolly the sheep. Where's my clone?

Senators: Long

hotspot

focus

entertainment

leisure time